GoodRx (GDRX) Stock: Buy, Sell, or Hold?
GDRX - GoodRx Holdings, Inc. Class A Common Stock
$3.27
-0.02 (-0.61%)
▼
5d:
-2.68%
30d:
-5.49%
90d:
+7.21%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When GDRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GDRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GDRX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$4.26
Based on 10.6% avg growth
INTRINSIC VALUE TODAY
$2.64
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GDRX is currently trading at $3.27, which is considered oversold relative to its 30-day fair value range of $3.33 to $3.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.2) compared to its historical average (7.3). At these levels, the market is pricing in 8.2% annual earnings growth.
Technical Outlook: Technically, GDRX is in a strong uptrend. The price is currently testing key support at $3.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GDRX scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.95 (+20.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GDRX is in a strong uptrend. The price is currently testing key support at $3.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GDRX scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.95 (+20.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.33 -
$3.52
Company Quality Score
43/100
(HOLD)
Options IV Signal
44th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
62.3%
Protect Your Profits
Holding GDRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 44th percentile)
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.8% below Wall St target ($3.95)
- BULLISH: Expecting earnings turnaround to 8.2% growth with -1.3% revenue growth
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.33 -
$3.52
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.53
(16.2%)
Support & Resistance Levels
Support Level
$3.21
Resistance Level
$3.46
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.22
Wall Street Target
$3.95
(+20.8%)
Revenue Growth (YoY)
-1.3%
Earnings Growth (YoY)
-44.5%
Profit Margin
2.1%
Valuation Premium vs History
+8.2% premium
PE vs Historical
9.2 vs 7.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.2%
(market-implied from PE analysis)
1-Year Target
$3.54
(+8%)
2-Year Target
$3.83
(+17%)
3-Year Target
$4.14
(+27%)
3-Yr Target (if PE normalizes)
(PE: 9→7)
PE COMPRESSION
$3.28
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 17.1%)
$11.62
(+255%)
Base:
(SPY PE: 9.2, Growth: 17.1%)
$5.25
(+61%)
Bear:
(PE: 7.3, Growth: 17.1%)
$4.16
(+27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Forward PE: 10.29 | Forward EPS (Implied): $0.32
Bull Case
$3.95
(+21%)
Analyst growth 15.0%, PE expands to 10.8
Base Case
$3.27
(0%)
Market implied 0.0%, PE stable at 10.3
Bear Case
$2.50
(-24%)
Severe decline -15.0%, PE contracts to 9.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 5:31 AM ET
Data refreshes hourly during market hours. Next update: 6:31 AM
Data refreshes hourly during market hours. Next update: 6:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GDRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$31 | 60 BUY |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$14 | 80 BUY |
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$297 | 41 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 56 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$119 | 51 HOLD |
Advanced GDRX Option Strategies
Professional options setups generated by AI based on today's GDRX price and gamma walls.
